CB 1 antinociceptive tolerance is delayed in S426A/S430A mice and accelerated in older mice in the formalin test of inflammatory pain
Molecular Pain · 2026
DOI: 10.1177/17448069261489964 ↗Kurz gefasst
Fachartikel in der Zeitschrift Molecular Pain, 2026. Verfasst von Robert C Barnes und 5 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacology and Neuroscience, Texas Tech University Health Sciences Center, School of Medicine, Lubbock, TX, USA. Hauptthemen laut MEDLINE: Receptor, Cannabinoid, CB1, Inflammation, Pain, Drug Tolerance. Die Arbeit nennt 105 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Texas Alzheimer’s Research and Care Consortium, The CH Foundation Grant, National Institute on Drug Abuse.
Abstract (Originalsprache)
Inflammatory pain represents a significant detriment to patient quality of life and currently lacks adequate treatment options. Conditions associated with inflammatory pain can occur across the lifespan but are most common in aged individuals. There has been increasing public interest in the analgesic potential of cannabinoids, and CB 1 agonists have been preclinically tested for several conditions. However, their use is potentially limited by the development of tolerance. The S426A/S430A transgenic mouse line was previously generated to explore this tolerance, with two point mutations preventing the phosphorylation that represents the first step in CB 1 desensitization. Therefore, we investigated the antinociceptive efficacy of CB 1 -selective agonism (ACEA) in the formalin model of inflammatory pain, using mice that varied in sex (female vs male), age (3- vs 12-month-old [MO], and genotype (C57BL/6J vs S426A/S430A). ACEA provided significant antinociception that was equivalent across all tested group. The S426A/S430A mutation significantly delayed tolerance at both ages tested. Additionally, the S426A/S430A mutation was associated with increased body weight in 3MO, 12MO female, and 12MO male mice. Mice that were 12MO had accelerated tolerance relative to 3MO mice. No significant differences in rotarod (motor coordination), open field (locomotion and center duration), or rectal temperature were noted. These results demonstrate the antinociceptive benefit of CB 1 agonists and the significant limitation in their use (tolerance). Further studies are needed to investigate the mechanisms of CB 1 tolerance development, the increase in body weight with the S426A/S430A mutation, and the potential clinical significance of these findings.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmacology and Neuroscience, Texas Tech University Health Sciences Center, School of Medicine, Lubbock, TX, USA.
- Center of Excellence for Translational Neuroscience and Therapeutics, Texas Tech University Health Sciences Center, School of Medicine, Lubbock, TX, USA.
- Brain Drug Discovery Center, Texas Tech University Health Sciences Center, Amarillo, School of Pharmacy, TX, USA.
ORCID-Profile: Aric F Logsdon, Josée Guindon
Förderung
- Texas Alzheimer’s Research and Care Consortium
- The CH Foundation Grant
- National Institute on Drug Abuse
- National Institute on Aging
Zitieren
APA
Barnes, R. C., Quick, H., Banjara, S., Robison, D., Logsdon, A. F., & Guindon, J. (2026). CB 1 antinociceptive tolerance is delayed in S426A/S430A mice and accelerated in older mice in the formalin test of inflammatory pain. Molecular Pain. https://doi.org/10.1177/17448069261489964
Vancouver
Barnes RC, Quick H, Banjara S, Robison D, Logsdon AF, Guindon J. CB 1 antinociceptive tolerance is delayed in S426A/S430A mice and accelerated in older mice in the formalin test of inflammatory pain. Molecular Pain. 2026. doi:10.1177/17448069261489964
BibTeX
@article{Barnes2026,
author = {Barnes, Robert C and Quick, Hannah and Banjara, Satish and Robison, Dakota and Logsdon, Aric F and Guindon, Josée},
title = {CB 1 antinociceptive tolerance is delayed in S426A/S430A mice and accelerated in older mice in the formalin test of inflammatory pain},
journal = {Molecular Pain},
year = {2026},
doi = {10.1177/17448069261489964}
}
EUVIMED